Nutriband: Addressing a Multi-Billion-Dollar Market Opportunity

May. 27, 2022
Nutriband (NASDAQ: NTRB) is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies, benefitting patients, physicians, and payers. Nutriband’s patented lead product technology, AVERSA®, is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse-deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the US, European Union, Australia, Japan, Mexico, and Russia, with patent protection pending in Canada. Nutriband is targeting all large applicable markets and its global patent protection provides multiple opportunities for the Company to make a significant impact on the safety profile of drugs globally. Visit to learn more.

 Read More

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market